09/06/2026
𝗔𝗚𝗣 𝗠𝗲𝗿𝗴𝗲𝗿: 𝗪𝗵𝘆 𝗧𝗵𝗶𝘀 𝗖𝗼𝘂𝗹𝗱 𝗕𝗲 𝗮 𝗠𝗲𝗮𝗻𝗶𝗻𝗴𝗳𝘂𝗹 𝗘𝗮𝗿𝗻𝗶𝗻𝗴𝘀 𝗜𝗻𝗳𝗹𝗲𝗰𝘁𝗶𝗼𝗻 𝗣𝗼𝗶𝗻𝘁 🧵
The proposed merger is much more than a corporate restructuring.
From a business owner's perspective, lets understand its implications :
What is actually happening?
The OBS Group plans to merge:
OBS Pharma (former Bayer portfolio)
OBS AGP (former Sandoz portfolio)
OBS Pakistan (former Pfizer portfolio)
into AGP Limited, making AGP the sole listed vehicle for the group's pharmaceutical operations.
The objective:
Achieving synergies in supply chain, marketing, financial optimization, product and risk diversification, ultimately leading to value creation for shareholders.
The merger is expected to become effective from Jan-2026, or any other date approved by the court.
Why the merger is strategically attractive
1. AGP becomes a significantly larger pharmaceutical franchise
Acc to JS Global estimates, post-merger:
• The profits are expected to grow much faster than revenue.
• This indicates the acquired businesses carry attractive margins
2. AGP gains dominant brands across multiple therapeutic categories
Before the merger, AGP's earnings were heavily dependent on a smaller portfolio led by Rigix and a few core brands.
After the merger, AGP owns a much broader collection of leading pharmaceutical franchises
3. Women's healthcare becomes a major growth engine
OBS Pharma is arguably the most strategically valuable piece of the transaction
Its flagship products, Gravibinan and Primolut N, are leaders in women's healthcare and contribute more than half of OBS Pharma's revenue
For investors, this matters because:
- Women's healthcare demand is relatively resilient
- Prescriptions tend to be recurring
- Competition is lower than generic drug category
-Pricing regulation risk is ↓
This should improve the quality and predictability of AGP's earnings
4. Higher exposure to non-essential drugs means better pricing power
This is important bcz non-essential medicines are not subjected to the pricing restrictions as essential drugs
After the merger, non-essential products are expected to contribute 68% of revenue vs 65% prev.
5. Synergies are excluded from current estimates
One most interesting aspects of the JS analysis is that their earnings estimates do not include potential benefits from:
Supply chain optimization
Marketing efficiencies
Lower operating costs
New product launches
¤ Cross-selling opportunities across doctor networks and distributors
¤ These are the classic benefits that usually justify pharmaceutical mergers.
If management executes well, actual earnings could exceed the initial projections.
6. EPS dilution exists but is manageable
A common concern is share dilution.
To complete the merger, AGP will issue approximately 109 million new shares, increasing total shares from roughly 280 million to 389 million.
However:
EPS still increases ~10–12%
The most compelling aspect is not the immediate earnings uplift.
The merger transforms AGP from separate pharmaceutical businesses into a unified healthcare platform.
This diversification ↓ dependence on 1 product or category while increasing cross-selling opportunities.
A broader product basket generally commands:
– Higher valuation multiples,
– Better negotiating power with distributors,
– More stable cash flows,
– Greater ability to launch new products successfully.
From a fundamental perspective, this corporate action that can create a multi-year earnings compounding story if management successfully integrate the businesses and capture the expected synergies.
If you find it valuable share your opinion and repost to share it with others
